An integrative multi-omics investigation has established a positive causal relationship between CLDN4 expression and ovarian cancer risk, identifying the gene as a candidate therapeutic target and diagnostic biomarker. The finding, supported by summary Mendelian randomization analysis at a significance threshold of P < 0.05, highlights CLDN4 among a broader set of genomic markers tied to disease risk and tumor immunology.
Ovarian cancer remains a highly lethal malignancy constrained by limited diagnostic biomarkers and therapeutic targets. In response to these clinical limitations, the research team designed a multi-phase computational and genetic workflow aimed at uncovering robust diagnostic signatures, characterizing immune infiltration patterns, and distinguishing causal disease drivers from non-causal associations.
To prioritize candidate genes across large-scale biological cohorts, the investigators integrated multiple public transcriptomic datasets from the Gene Expression Omnibus, The Cancer Genome Atlas, and the Genotype-Tissue Expression project. The team then applied differential gene expression analysis alongside weighted gene co-expression network analysis to isolate key co-expression modules and candidate genes from the combined expression data.
Candidate signatures were subsequently evaluated through an extensive machine learning pipeline incorporating 113 distinct models. When validated across independent patient cohorts, an eight-gene diagnostic signature composed of KDR, CLDN4, CAV1, BMP2, CLDN7, SNCA, FGF13, and AGTR1 demonstrated high diagnostic performance for identifying ovarian cancer cases.
Using the CIBERSORT algorithm to quantify immune cell composition within the tumor microenvironment, the researchers assessed how signature genes correlated with immune cell subsets. Among the evaluated targets, CAV1, FGF13, and KDR displayed positive correlations with M2 macrophage infiltration, suggesting potential mechanistic roles in immune evasion.
To establish causality beyond correlative expression patterns, the study performed summary Mendelian randomization by integrating blood expression quantitative trait loci data with genome-wide association study data from FinnGen. This genetic causal inference, combined with transcriptomic profiling and functional validation, established a positive causal link between CLDN4 expression and ovarian cancer risk, offering a verified foundation for translational oncology research.
Beyond the primary causal identification, the investigative framework relies on a multi-tiered validation structure designed to connect computational gene prioritization with actionable biological insight. The research strategy pairs transcriptomic associations derived from public expression repositories with genetic causal inference and experimental functional validation, creating a linked progression from computational discovery to laboratory confirmation in ovarian cancer pathology.
By grounding gene identification in independent cohorts and functional assays, the study addresses common obstacles in ovarian oncology, where limited diagnostic biomarkers and therapeutic targets have historically impeded clinical management. The integration of high-dimensional expression datasets with targeted causal modeling demonstrates how computational modeling pipelines, comprising 113 distinct model architectures, can isolate specific diagnostic candidates from complex genomic landscapes.
The study authors emphasize that these combined findings provide fresh perspectives on the molecular mechanisms governing ovarian cancer pathogenesis. Identifying CLDN4 as both an essential biomarker candidate and a prospective therapeutic target establishes an empirical baseline for future translational research, offering concrete molecular targets for subsequent experimental and clinical oncology investigations.
Subject of Research: Identification of CLDN4 as a causal gene and therapeutic target in ovarian cancer
Article Title: Multi-omics and functional validation identify CLDN4 as a therapeutic target in ovarian cancer
Article References: Ling, Q., Chen, Y., Wu, L., Xu, H., Zhang, Z., Chen, J., Lai, H., Yao, S., Zhao, R., Yang, G., & He, W. (2026). Multi-omics and functional validation identify CLDN4 as a therapeutic target in ovarian cancer. Discover Oncology. https://doi.org/10.1007/s12672-026-06291-4
Image Credits: AI Generated
DOI: 10.1007/s12672-026-06291-4
Keywords: ovarian cancer, CLDN4, summary Mendelian randomization, transcriptomics, machine learning, CIBERSORT, M2 macrophages, immune evasion, KDR, CAV1, FGF13, BMP2, CLDN7, SNCA, AGTR1, WGCNA, eQTL, FinnGen GWAS
News Source: Nathaniel Bowman. (November 13, 2026). CLDN4 Expression Causally Increases Ovarian Cancer Risk in Multi-Omics Study. Scienmag.



